Ambu corporate statement relating to modern slavery
Structure, business, and supply chain
Ambu develops, manufactures and sells medical devices to hospitals, clinics and rescue services all over the world. We employ 4,500 employees globally.
Our devices are single-use which means that they are only used during a single procedure for a specific patient. At the end of the procedure, they are discarded. The main advantages of single-use devices are that each patient is treated with a clean device – for improved patient safety – and that patient-ready devices are readily available.
We develop our products in close collaboration with healthcare professionals, in order to most effectively ensure that our solutions are relevant for our customers.
We own and operate factories in Penang (Malaysia), Xiamen (China), Indiana (USA) and Juárez (Mexico). Our expertise and continuous optimization efforts have resulted in an ability to uphold a high output of quality single-use devices at low costs.
Most of our revenue is generated through our own direct sales force, which has experience in single-use devices and is specialized within Visualization, Anaesthesia and Patient Monitoring & Diagnostics. Ambu has direct sales in 19 countries and sales via distributors on other markets.
As stated in the Ambu Code of Conduct, Ambu maintains the highest ethical standards and complies with all applicable laws, rules regulations and local customary practices.
Ambu respects the internationally recognized human rights of all people. We are committed to identifying and addressing any adverse impacts which may result from our own operations or business relationships. Ambu supports the principles contained within the Universal Declaration of Human Rights, the International Labour Organization’s Declaration on Fundamental Principles and Rights at Work and the UN Guiding Principles on Business and Human Rights.
As a signatory to the UN Global Compact, we are committed to its ten principles. Our commitment to the labour and human rights principles are reflected in our Code of Conduct for employees and our Code of Conduct for Business Partners.
Our commitment to human rights, which covers areas such as forced labour, slavery, child labour, sex trafficking, workplace abuse and human trafficking, is also outlined in our Labour and Human Rights guideline, available on www.ambu.com.
Ambu expects employees to avoid and mitigate all negative human rights impacts and to inform, through our management system or grievance mechanisms, any breach of this expectation or doubts that our expectations are being met.
Ambu expects its business partners to understand and address our expectations related to human rights and to inform employees of Ambu or through Ambu’s grievance mechanism if expectations are not being met.
Due to the nature of Ambu production and the skills needed to operate, the risk of forced labour and child labour are not considered material within Ambu’s direct operations. Ambu is aware that this may be different when it comes to suppliers. That is why Ambu works strategically and continuously to implement our Code of Conduct for Business Partners in our value chain based on risk assessments and spend. In cases of non-compliance Ambu seeks dialogue to improve conditions.
Ambu has implemented a process to screen and conduct due diligence of existing and new direct and finished goods suppliers for compliance with human rights and labour rights and is working to extend the process to all types of suppliers.
Ambu audits a number of suppliers each year based on a risk-based approach.
Ambu provides training for new and existing employees on our Code of Conduct as well as other polices. Going forward, Ambu will strengthen training on human trafficking and slavery, particularly with respect to mitigating risks within the supply chain, to employees who have direct responsibility for supply chain management.
Ambu will monitor the improvements as a result of the due diligence procedure and will communicate about this in the yearly Sustainability Report.
This statement was approved by the Ambu Board of Directors on November 09, 2022.